ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
InnoCare’s Zurletrectinib Receives Priority Review from China’s NMPA PharmaSources
May 06, 2025InnoCare Pharma announced today that its new generation pan-TRK inhibitor zurletrectinib (ICP-723) has been granted priority review by the CDE of China NMPA. -
InnoCare Announces the Acceptance of New Drug Application for pan-TRK Inhibitor Zurletrectinib in China PharmaSources
April 16, 2025InnoCare's zurletrectinib NDA for treating NTRK fusion - positive advanced solid tumors in adults and adolescents was accepted. It shows good efficacy and safety. -
InnoCare Announces First Pediatric Patient Dosed in Clinical Trial of pan-TRK Inhibitor Zurletrectinib in China PharmaSources
January 24, 2024Jan. 24, 2024 - InnoCare Pharma announced today that the first pediatric patient has been dosed in clinical trial with its second. -
InnoCare Announces Approval of Clinical Trial of pan-TRK Inhibitor Zurletrectinib for the Treatment of Pediatric Patients in China PharmaSources
July 27, 2023InnoCare announces approval of clinical trial of pan-TRK inhibitor Zurletrectinib for the treatment of pediatric patients in China.
Pharma Sources Insight January 2025
